Robeco Institutional Asset Management B.V. lowered its holdings in shares of Zoetis Inc. (NYSE:ZTS – Free Report) by 14.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 568,472 shares of the company’s stock after selling 95,039 shares during the period. Robeco Institutional Asset Management B.V. owned about 0.13% of Zoetis worth $92,621,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. State Street Corp raised its position in Zoetis by 0.5% during the third quarter. State Street Corp now owns 19,779,344 shares of the company’s stock worth $3,864,488,000 after acquiring an additional 95,856 shares during the last quarter. Geode Capital Management LLC raised its position in Zoetis by 1.8% during the third quarter. Geode Capital Management LLC now owns 10,427,760 shares of the company’s stock worth $2,030,813,000 after acquiring an additional 185,364 shares during the last quarter. Mizuho Securities USA LLC raised its position in Zoetis by 13,726.9% during the third quarter. Mizuho Securities USA LLC now owns 4,865,000 shares of the company’s stock worth $950,524,000 after acquiring an additional 4,829,815 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in shares of Zoetis by 5.3% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 3,896,106 shares of the company’s stock valued at $761,221,000 after buying an additional 194,542 shares during the last quarter. Finally, Clearbridge Investments LLC raised its position in shares of Zoetis by 5.8% in the second quarter. Clearbridge Investments LLC now owns 3,044,384 shares of the company’s stock valued at $527,774,000 after buying an additional 166,517 shares during the last quarter. Institutional investors and hedge funds own 92.80% of the company’s stock.
Zoetis Price Performance
ZTS opened at $170.32 on Wednesday. The company has a quick ratio of 2.27, a current ratio of 3.69 and a debt-to-equity ratio of 1.26. Zoetis Inc. has a 52-week low of $144.80 and a 52-week high of $200.53. The company has a 50 day moving average of $169.93 and a two-hundred day moving average of $179.65. The company has a market cap of $76.84 billion, a P/E ratio of 32.02, a P/E/G ratio of 2.57 and a beta of 0.89.
Zoetis Increases Dividend
The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, January 21st will be paid a dividend of $0.50 per share. This is an increase from Zoetis’s previous quarterly dividend of $0.43. This represents a $2.00 annualized dividend and a yield of 1.17%. The ex-dividend date of this dividend is Tuesday, January 21st. Zoetis’s payout ratio is currently 37.59%.
Analyst Upgrades and Downgrades
A number of equities analysts have recently weighed in on the stock. JPMorgan Chase & Co. boosted their price objective on shares of Zoetis from $225.00 to $230.00 and gave the company an “overweight” rating in a research report on Friday, October 11th. Stifel Nicolaus cut their price objective on shares of Zoetis from $210.00 to $180.00 and set a “buy” rating for the company in a research report on Tuesday, January 7th. Leerink Partnrs raised shares of Zoetis to a “strong-buy” rating in a research report on Monday, December 2nd. UBS Group assumed coverage on shares of Zoetis in a research report on Monday, December 9th. They issued a “neutral” rating and a $196.00 price objective for the company. Finally, Leerink Partners assumed coverage on shares of Zoetis in a research report on Monday, December 2nd. They issued an “outperform” rating and a $215.00 price objective for the company. One analyst has rated the stock with a hold rating, nine have issued a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $211.89.
View Our Latest Stock Report on Zoetis
Zoetis Profile
Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.
Further Reading
- Five stocks we like better than Zoetis
- How to Invest in the Best Canadian Stocks
- Top Analysts’ Picks for 2025: 3 of Morgan Stanley’s Favorites
- Uptrend Stocks Explained: Learn How to Trade Using Uptrends
- Why Salesforce Stock Could Be at Fresh Highs by February
- P/E Ratio Calculation: How to Assess Stocks
- Talos Energy: Time to Take a Plunge Ahead of New CEO Appointment?
Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS – Free Report).
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.